CliffBio
small molecule

MS CONTIN

MORPHINE SULFATE

Loss of exclusivity—loss of exclusivity
CompanyKNOA →See this company's full patent-cliff portfolio

Drug detail

Brand nameMS CONTIN
Active ingredientMORPHINE SULFATE
Strength30MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalMay 1987
Marketing statusRX

More from KNOA

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

MS CONTIN patent cliff — loss of exclusivity — | CliffBio